{"id":535483,"date":"2021-09-08T08:04:43","date_gmt":"2021-09-08T12:04:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-08T08:04:43","modified_gmt":"2021-09-08T12:04:43","slug":"caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BASKING RIDGE, N.J., Sept.  08, 2021  (GLOBE NEWSWIRE) &#8212; Caladrius Biosciences, Inc. (Nasdaq: CLBS) (\u201cCaladrius\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23<sup>rd<\/sup>\u00a0Annual Global Investment Conference to be held September 13-15, 2021.<\/p>\n<p>The presentation will be available on-demand through the H.C. Wainwright\u00a0conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021.<\/p>\n<p>If you are an institutional investor and would like to listen to the Company\u2019s presentation, please click on the following link to register for the conference: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MCJ6ggOpL5Zr36NG8H2KLD4rsmjdgtmQ9sBuAszKJDmB7Av1cjRLO6hfVgJPr89XCC_Zv3qXUshY9saLHcNJedV1JIb00qcPN7DjUI08KfDVfRj8PC-WuFirKTyMoXRlO5YLEqVRY7WWVuaWVWjO9Q==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/hcwevents.com\/annualconference\/<\/a>.<\/p>\n<p>\n        <strong>About Caladrius Biosciences<\/strong>\n      <\/p>\n<p>Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.<\/p>\n<p>The Company\u2019s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xpNL3H1kIl5p1faxvVEOQmfBKfN3lbVSJOJToc-gcpZRz2bmpW6gmIopK0fnqJq3ceS1nU8eYZ4d4zt2vpN9jI0rtxwm9wbFU9huA4ybcV8=\" rel=\"nofollow noopener\" target=\"_blank\">www.freedom-trial.com<\/a>) in the U.S. for the treatment of coronary microvascular dysfunction (\u201cCMD\u201d); CLBS12 (HONEDRA\u00ae in Japan), recipient of orphan designation for Buerger\u2019s Disease in the U.S. and, in Japan, recipient of a SAKIGAKE designation and eligible for early conditional approval for the treatment of critical limb ischemia (\u201cCLI\u201d) and Buerger\u2019s Disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (\u201cDKD).\u00a0For more information on the Company, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z6iTnA3eTy_Qi7XVoVMhtsTainSllquL5RkDeFOcRTZ8CGsA7PKXlk1EUB_4RRqyZ5SmR4UcDif6WjK8kxROsA==\" rel=\"nofollow noopener\" target=\"_blank\">www.caladrius.com<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong>\n      <\/p>\n<p>Investors:<br \/>Caladrius Biosciences, Inc.<br \/>John Menditto<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Phone:\u00a0908-842-0084<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=87BcTOBCY7ijwaRHXTNjFjg7jF3_gafnmv7W_71_uAeMim-IafIrXqRnF-qN1loBrPhTzH0VtCiebo0ogmOfWqBrXnNlNK_9usWZeQDJ3-M=\" rel=\"nofollow noopener\" target=\"_blank\"><u>jmenditto@caladrius.com<\/u><\/a><\/p>\n<p>Media: <br \/>Real Chemistry<br \/>Rachel Girard<br \/>Real Chemistry<br \/>Phone: 401-477-4030<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wBC5Bv6Zncd5xhJrhjWpHKbNiR-3XpSy9kqsnR1UO6kqRQgkJvKo4zqknOg-ZhJ9_eP4kRruQBr3nCkYYuPvRMdMFmIgO40-uS0gg1EICbc=\" rel=\"nofollow noopener\" target=\"_blank\">rgirard@realchemistry.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTRkYTA4YTctNDY1NS00MTEwLTg5NmItZTIwZDk2MjEwZjhmLTEwMzI4NjY=\/tiny\/Caladrius-Biosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Caladrius Biosciences, Inc. (Nasdaq: CLBS) (\u201cCaladrius\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd\u00a0Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright\u00a0conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. If you are an institutional investor and would like to listen to the Company\u2019s presentation, please click on the following link to register for the conference: https:\/\/hcwevents.com\/annualconference\/. About Caladrius &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Caladrius Biosciences, Inc. (Nasdaq: CLBS) (\u201cCaladrius\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd\u00a0Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright\u00a0conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. If you are an institutional investor and would like to listen to the Company\u2019s presentation, please click on the following link to register for the conference: https:\/\/hcwevents.com\/annualconference\/. About Caladrius &hellip; Continue reading &quot;Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-08T12:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=\",\"datePublished\":\"2021-09-08T12:04:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) &#8212; Caladrius Biosciences, Inc. (Nasdaq: CLBS) (\u201cCaladrius\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd\u00a0Annual Global Investment Conference to be held September 13-15, 2021. The presentation will be available on-demand through the H.C. Wainwright\u00a0conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021. If you are an institutional investor and would like to listen to the Company\u2019s presentation, please click on the following link to register for the conference: https:\/\/hcwevents.com\/annualconference\/. About Caladrius &hellip; Continue reading \"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:04:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-08T12:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=","datePublished":"2021-09-08T12:04:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTU3NiM0MzkyNzU2IzIwMjExNTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caladrius-biosciences-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}